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A disorder of surfactant metabolism
without identified genetic mutations
Silvia Montella1, Timothy J. Vece2, Claire Langston3, Paola Carrera4, Lawrence M. Nogee5, Aaron Hamvas6,7,
Angelo Manna1, Mara Cervasio8 and Francesca Santamaria1*
Abstract
Background: Surfactant metabolism disorders may result in diffuse lung disease in children.
Case presentation: We report a 3-years-old boy with dry cough, progressive hypoxemia, dyspnea and bilateral
ground glass opacities at chest high-resolution computed tomography (HRCT) who had no variants in genes
encoding surfactant proteins or transcription factors. Lung histology strongly suggested an abnormality of surfactant
protein. A 7-month course of pulse intravenous high-dose methylprednisolone plus oral hydroxychloroquine and
azithromycin led to gradual weaning from oxygen and oral steroids, and to improvement of cough and dyspnea. Over
the follow-up period, hydroxychloroquine and azithromycin were not withdrawn as cough and dyspnea re-appeared
at each attempt and disappeared at re-start. At 6 years of age chest HRCT still appeared unchanged, but clinical
symptoms or signs were absent.
Conclusions: In children suspected of inborn errors of pulmonary surfactant metabolism who do not have a recognized
genetic mutation, lung biopsy with consistent histology may help physicians to address the definitive diagnosis.
Keywords: Interstitial lung disease, Surfactant Biology and Pathophysiology, Genetic testing

Background
Pediatric diffuse lung disease (DLD) is a heterogeneous
group of uncommon disorders with impaired gas
exchange and diffuse infiltrates at chest imaging [1].
Deletions of or mutations in genes encoding proteins
important in surfactant production and function (SP-B,
SP-C, and ABCA3), surfactant catabolism (GM-CSF
receptor), or transcription factors important for surfactant
production (TTF1) or lung development (Fox F1) may
cause pediatric DLD [2]. The prognosis of surfactant
disorders is heterogeneous, with high mortality in SP-B
deficiency and variable severity in cases with mutations in
ABCA3 or SP-C [1, 3, 4]. Mutations of surfactant protein
genes are detected in most patients [2]. However, 20–30 %
of cases with histological pattern compatible with surfactant disorders have no identified mutation [1].
We report a young child in whom lung histology
strongly suggested a surfactant disorder, but no variants
conclusively classified as pathogenic in genes encoding
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surfactant proteins or transcription factors important for
surfactant production were found.

Case presentation
The child was a full-term male, born to unrelated parents. There was no family history of lung disease. At
birth he required no resuscitation. By age 3 years he
developed fever with dry cough and dyspnea. Chest Xray showed mild-to-moderate interstitial thickening, and
IgM for Mycoplasma pneumoniae was detected. After
21 days of clarithromycin, fever disappeared. Respiratory
symptoms persisted unchanged also after two-month
course of inhaled steroids and montelukast. By age
3.6 years he was admitted to our hospital with persistent
dry cough and dyspnea, and progressive hypoxemia. On
examination, he had fine crackles and expiratory
wheezes bilaterally. Transcutaneous oxygen saturation
(SpO2) was 90 % at room air, but rose to 98 % at 4 liters/
minute oxygen delivered by nasal cannula. The remainder examination also including neurologic assessment
was normal. He could not perform spirometry.
Structural cardiovascular abnormalities were excluded
at echocardiography. Serological investigations ruled
out C. pneumoniae, adenovirus, metapneumovirus,
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cytomegalovirus, and respiratory syncytial, influenza,
parainfluenza, Epstein-Barr, and human immunodeficiency viruses. Airways anomalies were not evident at
flexible bronchoscopy. We did not perform bronchoalveolar lavage because it has limited value in identifying
the specific DLD or guiding therapy [1]. A 24 h pHimpedance monitoring was normal. The sweat test was
negative and the genetic testing did not identify any
causative mutation of cystic fibrosis. Ultrastructural
analysis of nasal cilia was normal. Primary immune
defects were ruled out and serological testing for connective tissue disorders were negative. Thyroid function
was normal. Chest high-resolution computed tomography (HRCT) revealed multiple bilateral ground glass
opacities (Fig. 1a and b). A direct sequencing protocol
was applied to the coding regions and exon/intron
junctions of SFTPB, SFTPC, ABCA3, NKX2.1, and
NKX2.5 genes. Promoter and regulatory regions were
not analyzed because at present no mutation has been
described in these sites. Molecular analysis in these
genes did not reveal a pathogenic variant in the patient.
However, the IVS4+39 C>T heterozygous rare variant
(rs79253830) was identified in SFTPC by Sanger direct
sequencing. The child was also heterozygous for the
known ABCA3 single nucleotide polymorphisms
rs170447, rs313908, and rs149532.
A thoracoscopic lung biopsy was performed. Histology
showed widened alveoli with thickened alveolar septa
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infiltrated mainly by fibroblasts and lymphocytes, hyperplasia of type-II pneumocytes, and intra-alveolar accumulation of finely granular periodic acid Schiff-positive
material and several cholesterol crystals, suggesting pulmonary alveolar proteinosis and nonspecific interstitial
pneumonia. At electron microscopy, alveolar type II cells
lacked mature cytoplasmic lamellar bodies, while other
organelles appeared normal, which was consistent with
surfactant protein abnormality. In particular, type II cell
cytoplasm showed numerous small structures containing
irregular and poorly staining material (Fig. 2).
Pulse intravenous high-dose methylprednisolone (30 mg/
kg once daily for three successive days each month), oral
hydroxychloroquine (10 mg/kg once daily) and azithromycin (10 mg/kg once daily for three consecutive
days/week) were started. Prior to treatment, the patient underwent a six minute walking test that showed
a walk distance of 381 (72 % predicted) meters and a
minimum SpO2 during the walk of 81 %. Moreover, he
spent 89.4 % of the walk time with SpO2 <90 %. The
combined therapy led to gradual weaning from oxygen
and improvement of cough and dyspnea over seven
months. Oxygen and steroids were gradually withdrawn, but oral hydroxychloroquine and azithromycin
continued. Six months after steroids and oxygen were
stopped, a substantial improvement of exercise tolerance versus pre-treatment test was observed as walk
distance was 441 meters (83 % predicted), with

Fig. 1 Baseline high-resolution computed tomography scans. Sharply defined areas of ground glass opacity more marked in the left upper
lobe (a), in the middle lobe, lingula and right lower lobe (b). High-resolution computed tomography at the age of 6 years (after 3 years of oral
hydroxychloroquine and azithromycin) showing unmodified ground glass attenuation in the same areas, indicating lung damage stabilization
(c and d)
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Fig. 2 Type II pneumocyte cytoplasm. Numerous small structures
containing irregular and poorly staining material at electron microscopy

minimum SpO2 during the walk of 85 % and 45.5 % of
the walk time spent with SpO2 <90 %.
Over the follow-up, we tried to withdraw hydroxychloroquine and azithromycin, but cough and dyspnea
re-appeared at each attempt, and rapidly disappeared at
re-start. Currently, the subject is 6 years-old, adherence
to treatment is satisfactory, with no side effects. Repeated daily SpO2 showed values not lower than 98 % at
room air, with median overnight values of 96 % (min
74 %, max 99 %). He is still unable to perform spirometry. Chest HRCT is unchanged (Fig. 1c and d).

Discussion
In this child with no mutations in genes important for surfactant function and metabolism, lung biopsy suggested
surfactant dysfunction, but with some unusual features
including the absence of lamellar bodies. The significance
of this finding is unclear. However, considering the normal
ultrastructure of other cellular and nuclear membranes, it
is thought to be a real finding, unrelated to biopsy processing or handling. Given the patient’s phenotype, this
pattern is consistent with a disorder of surfactant
metabolism.
For infants or young children with clinical, imaging,
and/or histological features suggestive of DLD, testing
for genetic abnormalities associated with surfactant dysfunction and/or NKX2.1 is recommended [2]. Although
positive results may obviate the need for lung biopsy,
individuals with unresolved disease in whom mutations
are not found require tissue sampling for achieving a
definitive diagnosis and guiding further diagnostic and
therapeutic choices [1].
Indeed, the recent scheme for pediatric DLD includes
conditions with histology consistent with surfactant dysfunction disorder without a yet recognized genetic mutation [1, 5]. Actually, the sensitivity of genetic testing for
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surfactant dysfunction disorders was not formally evaluated and, although the frequency of false-negative results
cannot be precisely estimated, it has been assumed to be
low [1]. In particular, current analytical methods cannot
detect all mutations that cause surfactant disorders (i.e.,
large rearrangements identified by conventional Sanger
sequencing). Moreover, functionally significant variants
may be present in untranslated regions that are not
examined through routine clinical sequencing or in
other genes not yet associated to the disease [6]. In our
case, standard sequencing methodologies did not detect
mutations in SFTPB, ABCA3, and NKX2 genes, but only
identified the SFTPC IVS4 + 39C > T rare variant located
21 nucleotides downstream to the termination codon, in
the 3′UTR. Unfortunately, we could not perform RNA
analysis of the lung tissue and, although in silico algorithms did not predict an effect on RNA splicing, we
cannot definitely exclude a possible pathogenic role of
the IVS4+39 C>T variant. Furthermore, we cannot
exclude the presence of a second unidentified mutation
on the other allele.
As the child was heterozygous for known ABCA3 single nucleotide polymorphisms, homozygosity by descent
for the same rare ABCA3 allele is improbable. Thus, variants in untranslated regions of or deletions in ABCA3
unlikely explain the child’s illness, as such variants are a
small minority of reported disease-causing ABCA3
alleles and would have to be present on two different
ABCA3 alleles. Finally, given the complexity of surfactant synthesis, secretion, and catabolism, there are likely
to be as yet unidentified disorders of other molecules in
this pathway that, when mutated, result in a similar
histological phenotype.
Treatment of SP-C and ABCA3 abnormalities derives
from anecdotal experience. The variable clinical course
of pulmonary disease, combined with the lack of prospective randomized controlled trials, makes it difficult
to uniform treatment strategies [2]. Treatment is based
on the concept that suppressing inflammation is supposed to prevent the progression to pulmonary fibrosis.
Among the anti-inflammatory agents, steroids are the
preferred choice. As glucocorticoids increase ABCA3
expression in vitro [7], there is a rationale for intravenous pulse steroids use in ABCA3 deficiency. Given the
limited evidence of a beneficial effect on clinical outcomes and the well known side effects of immunosuppressive medications, whether or not to initiate a trial of
immunosuppressive therapy must be decided on an individual basis. If steroids are given, patients should be
closely monitored for side effects, including periodic
measurement of weight and height, glucose homeostasis,
bone density, and ophthalmologic screening. Hydroxychloroquine, an anti-malarial drug supposed to have
immunological effects [8], has also been often used for
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treating DLD in children. If this drug is administered,
eye exams must be routinely performed to look for retinal toxicity, although this complication is extremely rare
in children. Likewise, azithromycin has been used for its
anti inflammatory effects [1, 9]. As surfactant disorders
are incurable, supportive care is important for maintaining
optimal health status. This includes oxygen administration,
if required, and adequate nutritional support as well as
interventions to prevent infections such as pneumococcal
vaccine, annual influenza vaccination and routine childhood immunizations. Lung transplantation is an ultimate
option if progressive clinical deterioration unresponsive to
medical therapy develops [3, 4, 9]. In the current case, the
combined treatment of pulse methylprednisolone and
hydroxychloroquine plus azithromycin resulted in progressive clinical resolution and lung damage stabilization.
Finally, a close follow-up is crucial to monitor the progression of disease.

Conclusions
Our report confirms that in children with suspected surfactant dysfunction, genetic testing is strongly recommended
because it can provide a definitive diagnosis, may obviate
unnecessary procedures and interventions, and potentially
provide important prognostic information for families and
physicians [1]. Nevertheless, physicians should be aware of
the possibility of lung histology consistent with surfactant
disorder without a yet recognized genetic mutation.
Ethical approval
All procedures performed in this publication are in
accordance with the ethical standards of the institutional
and/or national research committee and with the 1964
Helsinki declaration and its later amendments or comparable ethical standards.
Consent
Written informed consent was obtained from the parents of the patient for publication of this Case report
and any accompanying images. A copy of the written
consent is available for review by the Editor-in-Chief of
this journal.
Abbreviations
DLD: Diffuse lung disease; HRCT: High-resolution computed tomography.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
SM and TJV collaborated with the drafting of the manuscript and
contributed to the study supervision. CL and MC were the pathologists who
made the histological diagnosis. PC made the genetic analysis. LMN and AH
discussed broadly the case and addressed the discussion. AM has made
contributions to acquisition of data, and followed-up the patient as pediatric
pulmonology resident. FS commented on, revised the final manuscript and
acted as group coordinator. All authors read and approved the final
manuscript.

Page 4 of 4

Acknowledgements
Authors are indebted to Professor Paolo Macchia, Federico II University,
Naples, Italy, who made the genetic analysis for NKX2.1 and NKX2.5 genes.
Author details
1
Department of Translational Medical Sciences, Federico II University, Via
Sergio Pansini, 5 – 80131 Naples, Italy. 2Department of Pediatrics, Baylor
College of Medicine, Texas Children’s Hospital, Houston, TX, USA.
3
Department of Pathology, Baylor College of Medicine, Texas Children’s
Hospital, Houston, TX, USA. 4Division of Genetics and Cell Biology, IRCCS
Ospedale San Raffaele, Milano, Italy. 5Department of Pediatrics, Division of
Neonatology, Johns Hopkins University School of Medicine, Baltimore, MD,
USA. 6Edward Mallinckrodt Department of Pediatrics, Division of Newborn
Medicine, Washington University School of Medicine, St. Louis, MO, USA.
7
Department of Pediatrics, Division of Neonatology, Ann and Robert H. Lurie
Children’s Hospital of Chicago, Northwestern University Feinberg School of
Medicine, Chicago, IL, USA. 8Department of Advanced Biomedical Sciences,
Anatomo-Pathology Unit, Federico II University, Naples, Italy.
Received: 27 August 2015 Accepted: 5 November 2015

References
1. Kurland G, Deterding RR, Hagood JS, Young LR, Brody AS, Castile RG, et al.
An official American Thoracic Society clinical practice guideline:
classification, evaluation, and management of childhood interstitial lung
disease in infancy. Am J Respir Crit Care Med. 2013;188:376–94.
2. Nogee LM. Genetic Basis of Children’s Interstitial Lung Disease. Pediatr
Allergy Immunol Pulmonol. 2010;23:15–24.
3. Percopo S, Cameron HS, Nogee LM, Pettinato G, Montella S, Santamaria F.
Variable phenotype associated with SP-C gene mutations: fatal case with
the I73T mutation. Eur Respir J. 2004;24:1072–3.
4. Wambach JA, Casey AM, Fishman MP, Wegner DJ, Wert SE, Cole FS, et al.
Genotype-phenotype correlations for infants and children with ABCA3
deficiency. Am J Respir Crit Care Med. 2014;189:1538–43.
5. Deterding RR. Infants and Young Children with Children’s Interstitial Lung
Disease. Pediatr Allergy Immunol Pulmonol. 2010;23:25–31.
6. Agrawal A, Hamvas A, Cole FS, Wambach JA, Wegner D, Coghill C, et al.
An intronic ABCA3 mutation that is responsible for respiratory disease.
Pediatr Res. 2012;71:633–7.
7. Mulugeta S, Gray JM, Notarfrancesco KL, Gonzales LW, Koval M, Feinstein SI,
et al. Identification of LBM180, a lamellar body limiting membrane protein
of alveolar type II cells, as the ABC transporter protein ABCA3. J Biol Chem.
2002;277:22147–55.
8. Braun S, Ferner M, Kronfeld K, Griese M. Hydroxychloroquine in children
with interstitial (diffuse parenchymal) lung diseases. Pediatr Pulmonol.
2015;50:410–9.
9. Vece TJ, Fan LL. Interstitial Lung Disease in Children Older Than 2 Years.
Pediatr Allergy Immunol Pulmonol. 2010;23:33–41.

Submit your next manuscript to BioMed Central
and take full advantage of:
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at
www.biomedcentral.com/submit

